US FDA Drug Office Reorg Enters Homestretch With Leadership Nods For Three Clinical Offices
Executive Summary
Hylton Joffe was named acting director of the new Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine but also will continue to serve as Office of New Drugs acting deputy director; agency veterans Ellis Unger and Julie Beitz also tapped for clinical office leadership roles in final stage of massive reorg.
You may also be interested in...
Genetic Metabolic Diseases Get Their Own US FDA Advisory Committee
In a first for rare diseases, a new standing committee will provide advice and recommendations on technical, scientific and policy issues related to medical products for genetic metabolic diseases.
New Translational Science Team Created In US FDA’s CDER To Aid Rare Disease Drug Development
The group is intended to help rare disease drug developers answer all the necessary questions about surrogate endpoints and markers before the application review cycle.
2020 In Review: US FDA New Drug Office’s COVID-19 Response Aided By Reorganization
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.